To see all protocols that comply with the WHO Essential Medicine List 
  1. Home

Protocols not endorsed

On this page
Expand all Collapse all Back to top
Protocol Reason Date
Genetic testing for the 15q13.3 duplication associated with hereditary mixed polyposis syndrome Very rare mutation 11/06/15
Protocol Reason(s) Date

ID 836 Differentiated thyroid adjuvant EBRT post-operative 

No clinical need.

25/05/2018

ID 841 Anaplastic thyroid definitive/adjuvant EBRT post-operative

No clinical need.

25/05/2018

ID 981 Central nervous system (CNS) medulloblastoma post-operative radical adjuvant EBRT

No clinical need.

10/08/2018

ID 3652 Breast neoadjuvant EBRT chemoradiation​

Lack of consensus.

30/10/2019

ID 3582 Pancreas pre-operative EBRT​​

No clinical need.

Insufficient evidence.

6/11/2019
Protocol Reason Date
ID 3920 Allogeneic reduced intensity conditioning fludarabine (oral) and low dose total body irradiation (TBI) Insufficient evidence 08/12/2020
ID TBC Allogeneic myeloablative conditioning protocol (haploidentical) busulfan fludarabine thiotepa and post-transplant cyclophosphamide Insufficient demand 26/08/2022
Protocol Reason(s) Date
ID 1387 Breast adjuvant CNF (cyclophosphamide mitozantrone fluorouracil) Insufficient evidence/superior alternatives 09/05/2014
ID 1388 Breast neoadjuvant CNF (cyclophosphamide mitozantrone fluorouracil) Insufficient evidence/superior alternatives 09/05/2014
ID 1340 Breast Metastatic ECisF (epirubicin cisplatin fluorouracil) Insufficient evidence/unacceptable toxicity 09/05/2014
ID 3504 Breast metastatic cisplatin Insufficient evidence/superior alternatives 30/08/2019
ID 3590 Breast metastatic carboplatin and nab-paclitaxel Insufficient evidence/patient population impossible to define 30/08/2019
ID TBC Breast neoadjuvant FEC-D, pertuzumab and trastuzumab Unacceptable toxicity/superior alternatives 30/08/2019
ID TBC Breast adjuvant pertuzumab, trastuzumab and chemotherapy Treatment protocol too broad 30/08/2019
ID TBC Breast neoadjuvant carboplatin, paclitaxel weekly and trastuzumab Insufficient evidence 30/08/2019
ID TBC Breast adjuvant pertuzumab, trastuzumab and paclitaxel Insufficient evidence 07/08/2020
Protocol Reason(s) Date
ID 624 Colorectal metastatic FOLFOX7 (fluorouracil leucovorin oxaliplatin) Insufficient evidence/unacceptable toxicity/superior alternatives/dose not justified/no clinical need 13/09/2013
ID1184 Colorectal metastatic XELOX biweekly Insufficient evidence/no clinical need 13/09/2013
Protocol Reason(s) Date
ID 674 Cervical recurrent cisplatin etoposide Insufficient evidence 03/05/2013
ID 684 Cervical locally advanced SCC carboplatin chemoradiation Insufficient evidence 03/05/2013
ID 691 Cervical locally advanced SCC cisplatin (three weekly) chemoradiation Unacceptable toxicity 03/05/2013
ID 1475 Vulval carcinoma advanced cisplatin fluorouracil chemoradiation Insufficient evidence/ unacceptable toxicity/ superior alternatives 03/05/2013
ID 1468 Uterine leiomyosarcoma adjuvant gemcitabine and docetaxel  Insufficient evidence 28/10/2015
ID 1593 Uterine malignant mixed mullerian tumour advanced cisplatin, cyclophosphamide and doxorubicin Superior alternatives available 28/10/2015
ID 643 Uterine malignant mixed mullerian tumour advanced epirubicin and carboplatin Insufficient evidence 03/11/2017
Protocol Reason(s) Date
ID 625 Head and neck salivary gland advanced carboplatin fluorouracil chemoradiation Insufficient evidence/ no clinical need 03/05/2013
ID 1153 Head and neck salivary gland carcinoma advanced cisplatin and fluorouracil No clinical need 03/05/2013
ID 1038 Thyroid advanced cisplatin and doxorubicin  Insufficient evidence 21/10/2016
ID 648 Thyroid advanced doxorubicin Insufficient evidence 21/10/2016
ID 1946 Head and neck advanced or metastatic fluorouracil  Insufficient evidence 21/10/2016
ID 1980 Head and neck SCC locally advanced or metastatic carboplatin (AUC 5) Superior alternatives available 21/10/2016
ID 3566 Head and neck squamous cell carcinoma metastatic cARBOplatin and capecitabine  Insufficient evidence 15/03/2019
ID 660 Olfactory neuroblastoma carboplatin etoposide Insufficient evidence 15/03/2019
Metastatic or recurrent head and neck carboplatin Superior alternatives available 15/03/2019
Salivary gland vinorelbine single agent Other - incorporated in ID 3559 Head and neck salivary gland advanced or metastatic ciSplatin and vinORELBine 15/03/2019
Nasopharyngeal carcinoma induction TPF chemoradiation Insufficient evidence and superior alternative available 22/05/2019 and 30/07/2021

Nasopharyngeal locally advanced cARBOplatin (weekly) chemoradiation (2 AUC 6 cycles)

 Insufficient evidence 08/10/2019
Protocol Reason(s) Date
ID 669 Chronic lymphocytic leukaemia CVP (CYCLOPHOSPHamide vinCRISTine Prednisolone)  Superior alternatives available 28/10/2014
ID 1363 Hairy cell leukaemia pentostatin No clinical need 28/10/2014
ID 569 Acute lymphoblastic leukaemia FRALLE Insufficient demand 16/10/2016
ID 1547 Chronic lymphocytic leukaemia bendamustine Superior alternatives available 16/10/2016
ID 1522 Acute myeloid leukaemia thioguanine Insufficient evidence 16/10/2016
ID 3811 Chronic lymphocytic leukaemia bendamustine and rituximab Superior alternatives available 14/08/2020
ID TBC High-risk APML ATO and arsenic consolidation without further maintenance Indication/combination not approved by TGA 07/09/2022
ID TBC  Acute lymphoblastic leukaemia FLAG-IDA Superior alternatives available 07/09/2022
Protocol Reason(s) Date
ID 1391 Cutaneous T cell lymphoma relapsed vorinostat Insufficient evidence/superior alternatives 07/03/2014
ID 1670 Lymphoma EPOCH (etoposide prednisolone vinCRISTine CYCLOPHOSPHamide DOXOrubicin) Superior alternatives available 28/10/2014
ID 632 Non hodgkins lymphoma R-CHOEP21 (RITUXimab CYCLOPHOSphamide DOXOrubicin VinCRIStine ETOPOside prednisolone) Insufficient evidence 28/10/2014
ID 912 Non-Hodgkin lymphoma R-CNOP ( RITUximab CYCLOPHOSPHamide mitozantrone vinCRISTine prednisolone ) Insufficient evidence/no clinical need 28/10/2014
ID 1136 Non-Hodgkin lymphoma FGIV ( gemcitabine IFOSFamide vinORELBine ) Superior alternatives available 19/10/2016
ID 1400 Hodgkin lymphoma IGEV ( IFOSFamide gemcitabine vinORELBine prednisolone ) Insufficient demand 16/10/2016
ID 663 Non-Hodgkin lymphoma FM ( fludarabine mitozantrone ) Insufficient demand 16/10/2016
ID 666 Non-Hodgkin lymphoma FCM ( Fludarabine CYCLOPHOSPHamide mitozantrone ) Insufficient demand 16/10/2016
ID 372 Hodgkins lymphoma mini-BEAM (carmustine, cytarabine, etoposide, melphalan) Insufficient demand 16/10/2016
ID 626 Hodgkins lymphoma mini-dexa BEAM (dexamethasone, carmustine, cytarabine, etoposide, melphalan) Insufficient demand 16/10/2016
ID 687 Non-Hodgkin lymphoma chlorambucil prednisolone  Superior alternatives available 16/10/2016
ID 1546 Non-Hodgkin lymphoma bendamustine Superior alternatives available 16/10/2016
ID TBC Hodgkin lymphoma bendamustine and brentuximab vedotin Indication/combination not approved by TGA 07/09/2022
Protocol Reason(s) Date
ID 1618 Malignant melanoma metastatic trametinib Superior alternatives available 12/09/2014
ID 1508 Conjunctival malignant melanoma adjuvant topical mitomycin Insufficient evidence 16/10/2016
Melanoma metastatic carboplatin and paclitaxel Insufficient evidence, superior alternatives available 15/06/2018
Protocol Reason(s) Date
ID 628 Multiple myeloma oral CID (cyclophosphamide idarubicin dexamethasone) Superior alternatives available 04/05/2012
ID 1259 Multiple myeloma CD (cyclophosphamide and dexamethasone) Insufficient evidence/superior alternatives 16/10/2016
ID 1392 Multiple myeloma CAD (cyclophosphamide DOXOrubicin dexamethasone) Insufficient demand 16/10/2016
ID 1484 Multiple myeloma CTD (cyclophosphamide (IV) thalidomide dexamethasone) Superior alternatives available 16/10/2016
ID 1738 Multiple myeloma thalidomide maintenance Insufficient demand 24/11/2017
ID TBC Multiple myeloma DCEP (cyclophosphamide etoposide cisplatin dexamethasone) Insufficient demand 24/05/2019
ID TBC Multiple myeloma KdD (carfilzomib daratumumab dexamethasone) Indication/combination not approved by TGA 07/09/2022
ID TBC Mulitple myeloma bortezomib selinexor dexamethasone  Insufficient demand 07/09/2022
ID TBC Multiple myeloma ixazomib lenalidomide dexamethasone Insufficient demand 07/09/2022
Protocol Reason(s) Date
ID 1448 Glioma recurrent carboplatin Insufficient evidence/ superior alternatives available/patient population impossible to define 4/10/2013
ID 1203 Glioma high grade recurrent dose dense temozolomide Insufficient evidence 12/09/2014
ID 692 Medulloblastoma adjuvant cisplatin lomustine vincristine Insufficient evidence 12/09/2014 (reviewed 06/03/2020)
ID 695 Oligodendroglioma carboplatin Insufficient evidence 12/09/2014
ID 696 Oligodendroglioma carboplatin and etoposide Insufficient evidence 12/09/2014

Glioblastoma recurrent temozolomide (metronomic dosing)

 Insufficient evidence (no consensus around optimum regimen to use) 17/08/2017
Protocol Reason(s) Date
ID 1698 Mesothelioma gemcitabine Insufficient evidence 18/11/2014
ID 647 NSCLC advanced gemcitabine and ginorelbine No clinical need/patient population impossible to define 12/09/2014
ID 1513 NSCLC locally advanced cisplatin and docetaxel chemoradiation Insufficient evidence 12/09/2014
ID 977 NSCLC epirubicin carboplatin and etoposide Insufficient evidence/no clinical need 12/09/2014
ID 1628 NSCLC nab-paclitaxel and carboplatin No clinical need 12/09/2014
ID 838 SCLC extensive disease oral etoposide Insufficient evidence/superior alternatives available 12/09/2014
ID 974 Mesothelioma carboplatin and gemcitabine Insufficient evidence 08/04/2016
NSCLC adjuvant gemcitabine and carboplatin Insufficient evidence 23/11/2018
NSCLC metastatic docetaxel and nintedanib Superior alternatives available 23/11/2018
ID 3954 NSCLC metastatic carboplatin pemetrexed ipililmumab and nivolumab Patient population impossible to define 30/04/2021
SCLC lurbinectedin Insufficient evidence 18/10/2021
SCLC lurbinectedin Insufficient demand 20/10/2022
Protocol Reason(s) Date
Kaposi sarcoma pegylated liposomal doxorubicin Insufficient evidence 08/10/2019
Soft tissue sarcoma dacarbazine Superior alternatives available 22/04/2021
Protocol Reason(s) Date
ID 714 Gastric advanced ELF (etoposide leucovorin fluorouracil)  Superior alternatives available 17/07/2013
ID 675 Gastric and oesophgel neoadjuvant carboplatin and fluorouracil  Insufficient evidence 16/10/2016
ID 1223 Gastric adjuvant fluorouracil chemoradiation No clinical need 16/10/2016
ID 717 Gastric advanced FLTAX (fluorouracil leucovorin PACLItaxel) Superior alternatives available 21/10/2016
ID 1377 Pancreas advanced gemcitabine and oxaliplatin No clinical need/insufficient demand 21/10/2016
ID 1521 Gastric, gastroesophageal and oesophageal advanced cISplatin and DOCEtaxel Superior alternatives available 21/10/2016
ID 1215 Gastric adjuvant capecitabine chemoradiation Insufficient evidence 27/06/2017
ID 3666 Gastric and gastroesophageal metastatic FLOT Insufficient evidence 09/02/2018
Hepatic advanced cabozantinib No clinical need/insufficient demand 01/07/2019
Pancreas neoadjuvant FOLFIRINOX (modified) Insufficient evidence 20/08/2020
Protocol Reason(s) Date
ID 1379 Prostate advanced goserelin and bicalutamide No clinical need 09/05/2014
ID 676 Testicular germ cell non seminoma adjuvant bleomycin etoposide carboplatin Insufficient evidence 27/03/2015
ID 2031 Bladder atezolizumab Insufficient evidence 19/05/2017
ID 3412 Renal cell carcinoma advanced lenvatinib and everolimus  Insufficient evidence 29/01/2018
ID 3565 Urothelial locally advanced or metastatic durvalumab Insufficient evidence/ Patient population impossible to define 15/03/2019
Urothelial metastatic nivolumab  Insufficient evidence/ Patient population impossible to define 15/03/2019
ID 3604 Bladder/urothelial capecitabine and mitomycin chemoradiation Insufficient evidence 23/10/2019
Prostate metastatic cabazitaxel, carboplatin and prednisolone Insufficient evidence 13/12/2019
ID TBC Bladder intravesical gemcitabine and docetaxel Insufficient evidence 07/08/2020

Send feedback for this page

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3315

05 Feb 2023